IMPEL PHARMACEUTICALS

*Based on the phase 3, open-label safety study that enrolled 360 patients with migraine, which assessed safety, tolerability, and exploratory efficacy of Trudhesa®. 7... Serious and/or life-threatening peripheral ischemia has been associated with the coadministration of dihydroergotamine with strong CYP3A4 inhibitors. Because CYP3A4 inhibition elevates the serum levels of dihydroergotamine, the risk for vasospasm leading to cerebral ischemia and/or ischemia of the extremities is increased. Hence, concomitant use of Trudhesa with strong CYP3A4 inhibitors is contraindicated... Cookies make most things better, including this site. By using this site, you agree to our cookie policy. For more information, read our Privacy Policy.

Also known as: Impel Pharmaceuticals Inc